This webinar is supported by Viatris.
Disclaimer: The views and opinions expressed in this webinar are those of the individual speakers and do not necessarily reflect those of Viatris or EMJ. The speaker received honoraria for participating in this webinar. UK Prescribing Information for Pimecrolimus can be found here. Adverse Event Reporting can be found at the end of this landing page. For those outside of the UK, please refer to your local guidance as prescribing conditions may vary.
In this EMJ webinar, Thomas Luger joins moderator Sue Saville to explore the latest evidence and practical guidance for managing mild to moderate atopic dermatitis (AD) in infants and children.
The discussion highlights a new topical corticosteroid-sparing algorithm designed to support daily clinical decision-making, with a focus on infants, children and sensitive skin areas.
Topics covered include:
- The treatment burden of AD in children
- The importance of early initiation of treatment
- The current treatment landscape and how to overcome unmet needs
- Key recommendations from EU experts on a new topical corticosteroid-sparing treatment approach for the treatment of mild-to-moderate AD in infants and children
Speaker
Thomas Luger
Department of Dermatology, Westphalian Wilhelms University, Münster, Germany
| Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Please report adverse drug reactions to Viatris at 0044 1707 853000 (select Option 5), or email: [email protected]. |
